The tablets Abilify MyCite with ingestion sensors

In the USA there were first tablets with a digital system tracking of their acceptance, Reuters reports. On November 13, 2017 their application in the country permitted Management on control of food and medicines of the USA (FDA/Food and Drug Administration).^[1]

The tablets Abilify MyCite are equipped with the special sensor allowing to monitor drug intake

It is about the medicine Abilify MyCite (ariprizol) which is released by the Japanese pharmaceutical company Otsuka Pharmaceutical. This medicine is intended for treatment of schizophrenia, bipolar disorder of the I type and a depression.

The tablets Abilify MyCite are equipped with the special sensor developed by Proteus Digital Health company which was approved by FDA to use in 2012. The sensor becomes more active under the influence of gastric juice and sends a signal to a special plaster which the patient carries on a body, and that, in turn, signals mobile application in the smartphone about drug intake, Bloomberg notes.

For the first time we had an objective instrument of control of observance by patients of instructions — Kabir Nath, the head of North American division of Otsuka Pharmaceutical said.

He hoped that the opportunity which appeared at doctors to trace how the patient takes medicine, will help to prevent the crisis situations arising when patients with schizophrenia miss medicine acceptance that leads to psychotic flashes because of which it is necessary to call Ambulance.

Patients to whom Abilify MyCite is written out will have to in writing to permit the doctor to obtain data on drug intake. At the same time the patient has a right to deny an information access to other people, including family members.

Also it is noted that Otsuka Pharmaceutical in partnership with several insurance companies is going to collect the aggregated anonymous data on the patients who gave the consent.^[2]

Notes